The gel sets in minutes — why placement has to be exact

Standard joint injections — corticosteroid, hyaluronic acid, PRP — are forgiving about exactly where the needle tip sits. As long as the fluid disperses inside the joint space, it reaches its target. ChondroFiller works on a fundamentally different principle, and that difference is what makes precision non-negotiable.

ChondroFiller is a Type I collagen hydrogel that must be deposited physically inside the cartilage defect itself — not into the surrounding joint fluid, but within the focal lesion. Once the 2.3 mL of gel is released, it begins to self-polymerise, bonding to the cartilage surface and forming a dimensionally stable three-dimensional scaffold within three to five minutes. After that window closes, the material has set. It cannot be repositioned, redistributed, or corrected. A needle that reaches the joint but misses the defect — landing a centimetre short in synovial fluid rather than inside the lesion — delivers no regenerative benefit whatsoever. There is no recovery from that error.

The imaging requirement follows directly from that biology. Real-time ultrasound allows the clinician to visualise the cartilage surface and the advancing needle tip simultaneously, confirming intralesional position on-screen before a single millilitre is deposited. It requires no ionising radiation and no theatre setting — the complete guided procedure takes place in a standard outpatient room. Where anatomy limits ultrasound access, fluoroscopic guidance can substitute, but clinic-based ultrasound is the dominant modality for ChondroFiller delivery.

The precision is not a preference or a regulatory formality. It is a direct consequence of how the gel behaves once it leaves the needle.

What the clinician sees on screen: mapping, tracking, confirming

Before the needle is even uncapped, the clinician runs a live ultrasound scan across the joint — not as a formality, but to build a working map of the defect. The screen shows the cartilage surface in real time, allowing the clinician to measure the lesion's size, gauge its depth, and define its edges. That spatial picture is what guides every decision that follows.

With the map established, the needle advances. This is not a blind approach followed by a check: the clinician watches the needle tip travelling toward the lesion on the ultrasound screen throughout its entire path. The image is live and continuous — more like a moving film than a series of snapshots.

Once the tip reaches the lesion boundary, the clinician pauses to confirm intralesional position on-screen. Only when the needle tip is verified to sit inside the defect — not merely within the joint space, but within the specific pocket of damaged cartilage — does gel deposition begin. The imaging remains active throughout, so any movement of the needle relative to the lesion is immediately visible.

This two-phase sequence — map the lesion, then track and confirm placement before releasing the scaffold — is what separates a ChondroFiller injection from a conventional intra-articular injection. A standard corticosteroid or hyaluronic acid injection targets joint space broadly; here, the target is a single focal pocket, and the ultrasound screen is what makes hitting it reliably possible.

Why anatomy makes landmark-only injection risky

Experienced clinicians can reliably identify broad anatomical landmarks — the anterior superior iliac spine, the femoral crease — but a focal cartilage defect is not a landmark. It is a millimetre-scale pocket within a joint surface, invisible to surface anatomy. That gap between what the skin reveals and where the needle needs to land is where landmark-only technique fails.

The Hoeber et al. 2016 systematic review and meta-analysis, drawing on 120 citations, quantified this for the hip: landmark-guided injections achieved accurate intra-articular placement in only 72% of cases (95% CI 56–85%), against 100% for image-guided approaches (p<0.0001). That 72% figure already represents a lower bar than intralesional accuracy — reaching the joint space is not the same as reaching the lesion within it.

Safety adds a further argument at the hip. The femoral nerve sits approximately 2.3 cm lateral to the anterior capsule, the femoral artery approximately 1.9 cm medial, and the femoral vein approximately 1.7 cm medial. The lateral circumflex femoral artery introduces additional complexity: it frequently courses directly over the anterior capsule at a position that varies between patients and cannot be assumed from surface landmarks alone.

The knee is a shallower joint and the neurovascular proximity is less acute, but the intralesional target is no less precise relative to the surrounding joint space. The accuracy requirement does not diminish with anatomy; only the specific risks differ.

Real-time ultrasound resolves both problems simultaneously. The relevant vessels become visible. The lesion boundaries become measurable. The needle tip appears on screen throughout its path. Guidance does not simplify the procedure — it makes the patient-specific anatomy legible, which is what allows placement to be reliable rather than merely probable.

What happens during the appointment

The appointment takes place in a standard outpatient clinic room — not a theatre. There is no surgical gown, no general anaesthetic, and no recovery bed. Patients arrive, have the procedure, and leave the same day.

The session opens with the clinician performing a live ultrasound scan to assess defect position and boundaries before preparing the needle. That imaging assessment feeds directly into the guided injection rather than sitting apart as a separate diagnostic stage. Once the needle has been tracked to confirmed intralesional position on screen — the two-phase sequence described in the previous section — 2.3 mL of collagen gel is deposited into the defect. The gel self-polymerises within three to five minutes and cannot be repositioned after setting, which is why the imaging confirmation step precedes deposition rather than following it. From initial scan to completion, the full session runs approximately 30 to 45 minutes.

Tolerability across published series is reported as good, and the overall complication rate is approximately 0.06% — a figure that reflects both the minimally invasive nature of the approach and the precision that image guidance provides.

Technique sensitivity is a real variable: the same product placed by different hands can yield different outcomes, and clinical experience with image-guided intralesional placement matters. Professor Paul Y. F. Lee leads Liquid Cartilage™ delivery at the London Cartilage Clinic on Harley Street — a factor patients frequently raise when deciding where to be assessed.

The days after: what's normal and what the 6-week window means

The six-week protection window is set by biology, not by administrative caution. Once the collagen gel has polymerised inside the defect, the scaffold enters its most vulnerable phase: progenitor cells recruited from the surrounding synovium and subchondral bone begin migrating into the matrix to initiate chondrogenesis. That early cellular infiltration and matrix remodelling cannot proceed normally under repeated mechanical load. Loading the joint prematurely risks deforming or displacing a scaffold that has gelled but has not yet integrated — which is why approximately six weeks of protected weight-bearing is standard, and for ankle procedures specifically, a CAM boot is the usual means of achieving it.

In the first one to three days, it is common to notice localised swelling, a temporary flare in pain, and crepitus — the clicking or popping sensation as the scaffold settles into position. These are recognised features of a normal post-injection response rather than signs of a problem; patients are pre-warned specifically so that day two does not prompt unnecessary concern.

Most patients manage the protection period within their ordinary routine. There is no surgical wound to dress and no inpatient stay to organise; the absence of both is one of the practical advantages that distinguish this pathway from a theatre-based procedure, even during the weeks when the joint needs careful handling.

Who benefits most and where to access ChondroFiller in London

The 70–85% rate of clinically meaningful symptom relief at three to five years, reported across four independent prospective cohorts, is a real number — but it is a patient-selection number as much as a product number.

Those results come from focal defects of approximately 3 cm² or less in joints graded Kellgren-Lawrence I–III. Diffuse, grade IV bone-on-bone arthritis falls outside that profile: the scaffold is designed for focal repair, and the joint environment in advanced disease does not reliably support the cellular recruitment the mechanism depends on.

This is also where the connection to ultrasound guidance closes. That evidence was generated in patients whose treatment was precisely placed — gel deposited intralesionally, inside the defect, not into surrounding joint fluid. The imaging confirmation step is not peripheral to the outcome data; it is part of what produces it. A product placed without image guidance cannot inherit the same evidence base, because the evidence was not generated that way.

The ChondroFiller injection pathway described throughout this article — ultrasound-guided, outpatient, without surgery or cell harvesting — is distinct from the Liquid Cartilage surgical protocol, which combines biological adjuncts with arthroscopic delivery.

For patients who broadly fit that profile, an assessment at the London Cartilage Clinic on Harley Street will confirm defect size, joint grade, and suitability through imaging review. Bookings at londoncartilage.com.